Effect of CPAP Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial
Primary Purpose
Pregnancy, Sleep-disordered Breathing, Gestational Diabetes
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
CPAP
Nasal dilator strip
Sponsored by
About this trial
This is an interventional treatment trial for Pregnancy
Eligibility Criteria
Inclusion Criteria:
- Pregnant women aged ≥ 18 y referred to the GDM clinic at the McGill University Health Centre
- >20 weeks and <34 weeks gestational age at time of recruitment
- Gestational diabetes
- Sleep-disordered breathing (SDB)
Exclusion Criteria:
- Pre-gestational type 1 or type 2 diabetes
- Multiple pregnancy
- Conception by IVF
- Prior treatment for SDB
- severe medical illness
- Severe SDB (AHI >30) and Epworth Sleepiness Scale >15 or oxygen desaturation index >30 or sustained hypoxia < 80%
- Habitual sleep duration on average less than 5 hours/night (determined by actigraphy)
- Cigarette smoking, alcohol consumption or illicit drug use
Sites / Locations
- McGill University Health Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
CPAP
Nasal dilator strip
Arm Description
Control
Outcomes
Primary Outcome Measures
Average nightly hours of CPAP use
Calculated over the course of pregnancy, with objective measurement from CPAP device download. CPAP will be initiated at time of diagnosis of sleep apnea after GDM diagnosis, and up until delivery of the baby (expected duration of 6-8 weeks)
Secondary Outcome Measures
Recruitment and retention rates in trial
Maternal glucose levels
Continuous glucose monitoring and capillary blood glucose checks
Full Information
NCT ID
NCT02245659
First Posted
April 25, 2014
Last Updated
February 15, 2021
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
1. Study Identification
Unique Protocol Identification Number
NCT02245659
Brief Title
Effect of CPAP Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial
Official Title
The Effect of Continuous Positive Airway Pressure (CPAP) Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
December 2018 (Actual)
Study Completion Date
December 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Clinical trial on effects of continuous positive airway pressure (CPAP) on glucose levels in pregnant patients with sleep-disordered breathing and gestational diabetes
Detailed Description
Gestational diabetes (GDM), defined as glucose intolerance that is first recognized during pregnancy, is associated with adverse maternal and fetal outcomes. Sleep-disordered breathing (SDB) is characterized by breathing pauses during sleep leading to recurrent arousals and intermittent hypoxia. The resulting increases in sympathetic drive, cortisol and inflammation have been shown to lead to glucose dysregulation. In that SDB is prevalent during pregnancy, SDB may represent a novel risk factor for GDM, as suggested by recent observational studies. No interventional studies evaluating the effects of SDB treatment on GDM outcomes have yet been published.
General Objective: To perform a pilot study to assess the feasibility of conducting a randomized-controlled trial using continuous positive airway pressure (CPAP) to evaluate the effects of SDB treatment on maternal-fetal outcomes in GDM.
Primary Aim of Pilot Study: 1) To assess CPAP adherence in pregnant patients with GDM. Secondary Aims: 2) To assess recruitment and retention rates over ~2 months of treatment 3) To assess adequacy of nasal dilator strips as the control intervention 4) To measure maternal glucose levels to determine sample size calculations for a future large-scale multi-site randomized-controlled trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Sleep-disordered Breathing, Gestational Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CPAP
Arm Type
Experimental
Arm Title
Nasal dilator strip
Arm Type
Other
Arm Description
Control
Intervention Type
Device
Intervention Name(s)
CPAP
Intervention Description
Continuous Positive Airway Pressure
Intervention Type
Other
Intervention Name(s)
Nasal dilator strip
Other Intervention Name(s)
Breathe-Right Strip
Intervention Description
Nasal dilator strip to be worn nightly
Primary Outcome Measure Information:
Title
Average nightly hours of CPAP use
Description
Calculated over the course of pregnancy, with objective measurement from CPAP device download. CPAP will be initiated at time of diagnosis of sleep apnea after GDM diagnosis, and up until delivery of the baby (expected duration of 6-8 weeks)
Time Frame
Up to 8 weeks
Secondary Outcome Measure Information:
Title
Recruitment and retention rates in trial
Time Frame
At completion of study (prior to delivery of baby)
Title
Maternal glucose levels
Description
Continuous glucose monitoring and capillary blood glucose checks
Time Frame
Throughout pregnancy until delivery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant women aged ≥ 18 y referred to the GDM clinic at the McGill University Health Centre
>20 weeks and <34 weeks gestational age at time of recruitment
Gestational diabetes
Sleep-disordered breathing (SDB)
Exclusion Criteria:
Pre-gestational type 1 or type 2 diabetes
Multiple pregnancy
Conception by IVF
Prior treatment for SDB
severe medical illness
Severe SDB (AHI >30) and Epworth Sleepiness Scale >15 or oxygen desaturation index >30 or sustained hypoxia < 80%
Habitual sleep duration on average less than 5 hours/night (determined by actigraphy)
Cigarette smoking, alcohol consumption or illicit drug use
Facility Information:
Facility Name
McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A2Y3
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30505290
Citation
Pamidi S, Meltzer SJ, Garfield N, Lavigne L, Olha A, Khalyfa A, Benedetti A, Tremblay G, Gagnon R, Rey E, Dasgupta K, Kimoff RJ. A Pilot Randomized-Controlled Trial on the Effect of CPAP Treatment on Glycemic Control in Gestational Diabetes: Study Design and Methods. Front Endocrinol (Lausanne). 2018 Nov 16;9:659. doi: 10.3389/fendo.2018.00659. eCollection 2018.
Results Reference
derived
Learn more about this trial
Effect of CPAP Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial
We'll reach out to this number within 24 hrs